Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

Timothy E Albertson, Willis S. Bowman, Richart W Harper, Regina M. Godbout, Susan Murin

Research output: Contribution to journalReview article

1 Scopus citations


The use of inhaled, fixed-dose, long-acting muscarinic antagonists (LAMA) combined with long-acting, beta2-adrenergic receptor agonists (LABA) has become a mainstay in the maintenance treatment of chronic obstructive pulmonary disease (COPD). One of the fixed-dose LAMA/LABA combinations is the dry powder inhaler (DPI) of umeclidinium bromide (UMEC) and vilanterol trifenatate (VI) (62.5 µg/25 µg) approved for once-a-day maintenance treatment of COPD. This paper reviews the use of fixed-dose combination LAMA/LABA agents focusing on the UMEC/VI DPI inhaler in the maintenance treatment of COPD. The fixed-dose combination LAMA/LABA inhaler offers a step beyond a single inhaled maintenance agent but is still a single device for the COPD patient having frequent COPD exacerbations and persistent symptoms not well controlled on one agent. Currently available clinical trials suggest that the once-a-day DPI of UMEC/VI is well-tolerated, safe and non-inferior or better than other currently available inhaled fixed-dose LAMA/LABA combinations for COPD.

Original languageEnglish (US)
Pages (from-to)1251-1265
Number of pages15
JournalInternational journal of chronic obstructive pulmonary disease
StatePublished - Jan 1 2019



  • COPD
  • fixed-dose combination inhalers
  • LABA
  • LAMA
  • long-acting beta2-adrenergic agonists
  • long-acting muscarinic antagonists
  • umeclidinium bromide
  • vilanterol trifenatate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this